Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538-07: Nivolumab in esophageal squamous cell carcinoma
jRCT2080222372Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Ono Pharmaceutical. Primary endpoint: Efficacy outcomes. Started Jan 2014; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2080222372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222372.